Wen is among the 40 finalists heading to Washington D.C. Thursday to present their projects to panels of experts. The winners ...
Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.73% to $687.15 Wednesday, on what proved to be an all-around favorable ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...
Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are ...
Zacks Investment Research on MSN2d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugRegeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback